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in asthma control: A pilot study*
Temperatura do ar exalado, um novo biomarcador  
no controle da asma: Um estudo piloto
Raul Emrich Melo, Todor A. Popov, Dirceu Solé
Abstract
Objective: To evaluate whether the exhaled breath temperature (EBT), measured by a noninvasive method, is 
an effective means of monitoring patients with uncontrolled asthma. Methods: A pilot study comprising nine 
patients (seven women and two men; mean age: 39 years) diagnosed with asthma at least one year prior to the 
beginning of the study and not having been under maintenance therapy for the last three months. In the first visit, 
the patients underwent spirometry and measurement of EBT. The patients were then instructed to use inhaled 
budesonide/formoterol (200/6 µg) every 12 h for six weeks. In addition, the patients with severe asthma (FEV1 < 
60% of predicted) were instructed to use oral prednisolone (40 mg/day) for five days. After six weeks, the patients 
underwent the same tests. Results: All of the patients reported an improvement in the symptoms of asthma, as 
confirmed by a statistically significant increase in FEV1 from the first to the second visit (mean, 56.1% vs. 88.7% 
of predicted; p < 0.05). Five patients used oral prednisolone for the first five days of the treatment period. Six 
patients used additional doses of inhaled budesonide/formoterol (mean duration, 2.5 weeks). The EBT decreased 
significantly from the first to the second visit (mean EBT: 35.1°C vs. 34.1°C; p < 0.05). Conclusions: Uncontrolled 
asthma, especially during exacerbations, is followed by an increase in EBT, which decreases after appropriate 
asthma control, as demonstrated by an increase in FEV1 and an improvement of the reported symptoms. These 
preliminary results suggest that EBT can be used as a parameter for the assessment of asthma control.
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Resumo
Objetivo: Avaliar se a temperatura do ar exalado (TAE), medida por um método não invasivo, é efetiva no 
monitoramento de pacientes com asma não controlada. Métodos: Estudo piloto com nove pacientes (sete 
mulheres e dois homens; média de idade: 39 anos) com diagnóstico de asma por pelo menos um ano e sem uso de 
tratamento de manutenção por pelo menos três meses antes do início do estudo. Na primeira visita, os pacientes 
foram submetidos à espirometria e à medida da TAE. Todos os pacientes foram orientados a iniciar tratamento 
com budesonida/formoterol (200/6 µg) inalatório a cada 12 h por seis semanas. Além disso, os pacientes com asma 
grave (VEF1 < 60% do previsto) foram orientados a utilizar prednisolona oral (40 mg/dia) por cinco dias. Após seis 
semanas, os pacientes foram submetidos aos mesmos testes. Resultados: Todos os pacientes relataram melhora 
dos sintomas de asma; confirmada por um aumento significativo de VEF1 da primeira para a segunda visita (média 
de VEF1: 56,1% vs. 88,7% do previsto; p < 0,05). Cinco pacientes utilizaram prednisolona oral, mas somente nos 
cinco dias iniciais do tratamento. Seis pacientes utilizaram doses extras da medicação inalatória (média de tempo 
de uso de medicação adicional = 2,5 semanas). Houve uma diminuição significativa da TAE entre os momentos 
de avaliação (média de TAE: 35,1°C vs. 34,1°C; p < 0,05). Conclusões: A asma não controlada, sobretudo durante 
exacerbações, é acompanhada pela elevação da TAE, que se reduz após o controle adequado da asma, demonstrado 
pela melhora do VEF1 e dos sintomas referidos. Esses resultados preliminares apontam para o monitoramento da 
TAE como um parâmetro possível na avaliação do controle da asma.
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(X-halo®; Delmedica Investments Pte Ltd., 
Singapore) also demonstrated that EBT is higher 
in patients with uncontrolled asthma.(9) The use 
of this device has simplified the technique, since 
the air is exhaled directly into the device, the 
mechanism of which is the same as that of a 
thermos and maintains heat in its copper core 
until the temperature—which tends to suffer less 
interference from the external environment—
stabilizes (Figure 1). The plateau measured also 
makes it unnecessary to calculate the difference 
in temperature or the peak temperature. 
In the present study, we used the 
aforementioned device (second generation) 
to evaluate adolescent and adult patients 
with asthma before and after asthma control. 
The treatment given, which consisted of a 
variable regimen of inhaled corticosteroid and 
bronchodilator, aimed to control the symptoms 
effectively until the end of a six-week follow-up 
period. 
Methods
The present study was conducted in the 
Allergy, Clinical Immunology, and Rheumatology 
Section of the Department of Pediatrics of the 
Federal University of São Paulo, in the city of São 
Paulo, Brazil, and included nine atopic patients 
aged 10-68 years who were diagnosed with 
uncontrolled asthma at the initial visit and were 
able to perform the procedures appropriately. 
All of the patients were diagnosed with 
asthma in accordance with the American Thoracic 
Society criteria(10) and presented immediate skin 
reactivity to Dermatophagoides pteronyssinus 
antigen (code 110/2; IPI ASAC Brazil, São 
Paulo, Brazil). In addition, the patients met the 
following inclusion criteria: 
•	not	having	had	respiratory	infection	in	the	
four weeks prior to the initial visit
•	not	having	cardiovascular	disease
•	being	a	nonsmoker
•	being	 able	 to	 perform	 forced	 expiratory	
maneuvers, using the device, at each 
respiratory cycle, for 5-10 min
•	being	able	to	perform	pulmonary	function	
tests with reproducibility
•	not	being	under	treatment	with	medication	
at the first evaluation
•	having	uncontrolled	asthma,	as	confirmed	
by altered pulmonary function test results
Introduction
Cellular infiltration of the mucosa, edema, 
epithelial damage, exaggerated production of 
mucus, and bronchospasm are well-known 
aspects of asthma. In clinical practice, the 
degree of inflammation, which is an important 
component of the monitoring of asthma 
patients, is noninvasively estimated by the 
symptoms reported by patients and by their 
recent history.(1) Therefore, patients who have 
recently experienced asthma attacks and those 
who complain of nocturnal symptoms, dyspnea, 
and cough after exercise, as well as those who 
experience exacerbations caused by everyday 
stimuli, are classified as having uncontrolled 
asthma, in accordance with the current 
guidelines for asthma management, which 
are based on the most recent revision of the 
Global Initiative for Asthma (GINA) guidelines.
(2) It is reasonable to assume that, in such cases, 
bronchoscopy with biopsy would show infiltrate 
characteristic of bronchial inflammation, which 
can be eosinophilic—in patients with allergic 
asthma who respond to corticosteroids—or 
neutrophilic—in patients who do not respond 
well to corticosteroids and generally present 
with severe asthma.(3) 
There seems to be a direct relationship 
between bronchial inflammation and the 
symptoms reported. However, there is a need 
for objective measurements. There are now 
many noninvasive methods for measuring 
inflammatory cells, mediators, or products 
(in blood, induced sputum, exhaled breath, 
and exhaled breath condensate).(4-6) However, 
bronchospasm, which is evaluated by pulmonary 
function testing (considered the gold standard 
and widely available), is the only other facet of 
asthma that can be objectively evaluated. 
Recently, a quite simple and yet innovative 
hypothesis—that inflammation produces one 
of its cardinal signs (i.e., heat) also in the 
bronchial lumen—resulted in the publication of 
two studies that examined the measurement of 
exhaled breath temperature (EBT). One group 
of researchers from the United Kingdom(7) and 
another from Italy(8) noted, through different 
methods, that the EBT was higher in patients 
with asthma. We find it interesting that both 
groups also noted a correlation between EBT 
and the level of exhaled NO. In 2007, a study 
employing a new device for measuring EBT 
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the Brazilian Thoracic Association.(11) For each 
pulmonary function measurement, we considered 
only the best one of the three curves obtained in 
three consecutive measurements. 
The device used in order to determine EBT 
consisted of a portable exhaled breath collector, 
similar to a thermos, into which patients exhaled 
repeatedly, through a valve mouthpiece, for 
5-10 min until the temperature, as measured 
by a digital thermometer, stabilized. At each 
new exhalation, the air that was collected in the 
compartment was expelled and was therefore 
replaced as the temperature of the central metal 
tube gradually increased. 
After the initial evaluation, the patients 
were instructed to use budesonide (200 µg) 
and formoterol (6 µg), administered via the 
Turbuhaler® system, every 12 h, as well as to 
repeat the dose whenever symptoms appeared, 
in accordance with a concept involving the use 
of this combination of drugs for the relief and 
control of asthma.(12) In addition, the patients 
received a diary to record how many doses of oral 
medication and of the budesonide/formoterol 
combination they used. 
The Wilcoxon test was used in order to 
compare the data obtained at the two evaluation 
time points. 
Results
Although the device used in the present 
study is considered easy to use (patients only 
have to press a button and blow into the 
mouthpiece), six preselected patients diagnosed 
with asthma (after anamnesis and pulmonary 
function testing) were unable to measure EBT 
successfully. Of those six, five were children 
(two 7-year-old girls, two 8-year-old boys, ad 
one 9-year-old boy), and one was a 26-year-old 
woman. These patients were not included in 
the study because they were unable to sustain 
the constant expiratory flow needed in order 
to increase the temperature progressively until 
it stabilizes and thus maintain the digital 
thermometer active. When the temperature 
increase was not sufficiently rapid, the display 
showed an error message, indicating a failure 
(increased resistance to the expiratory flow 
making it difficult to perform the maneuver, 
principally for the children). This problem should 
be corrected in future models of the device. The 
latest version of the device (Figure 2) has a USB 
The patients were also submitted to specific 
anamnesis. After the patients had given written 
informed consent, EBT was measured, and a 
pulmonary function test was performed with a 
MicroDL spirometer (Micro Medical Ltd., Kent, 
United Kingdom) and the program Spida 5 
(Micro Medical Ltd.), the patients being in the 
orthostatic position and using a nose clip. We 
evaluated FEV1, which was expressed as the 
percentage of the predicted value for gender 
and age in accordance with the guidelines of 
Figure 1 - Simplified schematic illustration showing 
the X-halo® device—1: air is exhaled into a valve 
mouthpiece; 2: air enters the chamber; 3: excess air 
is pushed out of the device; 4: copper tube (“metal 
heart”); and 5: temperature is recorded until it 
stabilizes.
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Figure 2 - Photograph of the latest-generation X-halo® 
device with a frontal USB port and interchangeable 
mouthpiece. The bottom part can be unscrewed for 
cleaning after each measurement. The mouthpiece 
glows green when the device is ready for use.
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In the second visit, six weeks after the first, 
all of the patients reported an improvement 
in the symptoms of asthma, as confirmed by 
a statistically significant increase in the mean 
FEV1 from the first to the second visit (56.1% vs. 
88.7% of predicted; p < 0.05). Conversely, the 
mean EBT decreased significantly from the first 
to the second visit (35.1°C vs. 34.1°C; p < 0.05). 
Six patients used additional doses of inhaled 
budesonide/formoterol (Table 1). 
Discussion
Various noninvasive biological markers 
have been proposed for the evaluation of 
bronchial inflammation, which is a fundamental 
aspect of the pathophysiology of asthma. For 
lack of a universal, practical method (as is 
pulmonary function testing for the evaluation 
of bronchospasm), these markers have not been 
used as a monitoring parameter in routine 
clinical practice. 
Analysis of induced sputum, which has 
played an increasingly important role in 
screening protocols, is a safe technique(4) that 
has great potential for the study of mediators in 
the bronchial tree. Analysis of induced sputum 
has been used in order to evaluate mediators 
such as IL-18, which has thus been shown to be 
decreased in asthma patients who smoke.(13) This 
inverse correlation between IL-18 and smoking 
has yet to be fully elucidated. In parallel with an 
increase in IL-8, the presence of neutrophils(14) 
can provide clues to the understanding of 
refractory asthma. However, analysis of induced 
port for computers and allows the visualization 
of the temperature curve by means of a program 
designed especially for that purpose. 
The nine patients included in the present 
study were able to measure EBT adequately 
and completed the protocol. All of the patients 
had uncontrolled asthma, and five showed 
FEV1 values < 60% of predicted, characterizing 
a severe asthma attack, according to the GINA 
consensus.(2) As shown in Table 1, these patients 
were treated with inhaled albuterol (400 µg), 
improved rapidly, and were instructed to start 
using oral prednisolone (40 mg/day). None of 
the patients evaluated had to use a new course 
of oral corticosteroids after the first five days of 
monitoring. 
Figure 3 - Graph of the exhaled breath temperature 
(°C) at the beginning and at the end of the study. 
Each solid line represents one patient. The dashed line 
represents the mean value for the group. *Wilcoxon 
test.
Table 1 - Age, gender, exhaled breath temperature, FEV1, and use of medication for asthma control.
Patients Age 
(years)
Gender Exhaled breath 
temperature
FEV1 Oral  
medication
Mean number 
of doses of 
budesonide+formoterol(°C) (% of predicted)
Initial Final Initial Final
1 12 M 35.58 34.18 72 98 Not used 1 dose every 12 h
2 68 F 34.56 33.71 38 63 Prednisolone (5 days) 1.5 doses every 12 h
3 32 M 35.81 34.95 62 93 Not used 1 dose every 12 h
4 42 F 35.13 33.51 67 98 Not used 1.8 doses every 12 h
5 48 F 34.55 33.54 41 95 Prednisolone (5 days) 1.5 doses every 12 h
6 41 F 34.50 33.91 50 103 Prednisolone (5 days) 1.4 doses every 12 h
7 55 F 34.51 33.90 78 91 Not used 1 dose every 12 h
8 43 F 35.63 34.76 41 84 Prednisolone (5 days) 2.1 doses every 12 h
9 10 F 35.62 34.81 56 73 Prednisolone (5 days) 1.2 doses every 12 h
Mean - - 35.10 34.14* 56.1 88.4* - -
Median - - 35.13 33.91* 56.0 93.0* - -
*p < 0.005 vs. initial (Wilcoxon test).
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patients from normal individuals (or from those 
with controlled asthma). 
When the air exhaled from the lungs is 
investigated using methods other than the 
analysis of exhaled breath condensate, one 
marker stands out: NO, a molecule that is found 
in the entire body in immune reactions and in 
neurotransmission. The NO synthase enzyme 
induces the production of L-arginine. In the 
analysis of exhaled NO, serial measurements 
seem to be more useful than are isolated 
measurements,(23) since the values of the 
latter in normal individuals and in those with 
asthma can overlap, as typically occurs for the 
two-tailed curves obtained in population-based 
studies. Numerous studies have investigated the 
exhaled NO fraction, which is closely related to 
eosinophilic inflammation.(5) In addition, the use 
of corticosteroids in COPD and asthma patients(24) 
is accompanied by a reduction in the exhaled NO 
fraction, which is not widely evaluated due to 
the lack of portability and cost of the devices 
needed in order to measure it. 
An increasing number of studies have 
investigated the analysis of EBT, which is a 
new, direct, noninvasive method for detecting 
a biomarker that might be useful in medical 
practice.(7) In the various tissues, inflammation 
causes the classic signs of pain, heat, edema, 
hyperemia, and function loss. At least with 
regard to increased production of local heat 
and hyperemia, inflammation (from the 
Latin inflammatio, meaning “to catch fire”) 
also seems to induce equivalent changes in 
the bronchial walls of patients with asthma, 
possibly due to vasodilation. In fact, increased 
bronchial vascularization and blood flow have 
previously been demonstrated.(25) Although the 
first studies of the physiology of heat exchange 
in the respiratory tree date from the 1960s and 
studies of the evolution of the observation of 
the differences in the temperature in each 
bronchial segment—as well as the relationship 
between these differences and the inhaled 
breath temperature—date from the 1980s,(26) the 
first studies involving direct measurements of 
EBT were not conducted until the beginning of 
the 21st century.(7,8) 
The first studies of exhaled air, which were 
published in 2002,(7,8) compared the measurements 
of two markers: temperature and NO. The initial 
impression of the authors of those studies was 
sputum requires specific knowledge and 
techniques in order to be effectively applied. 
To date, this test has principally been used for 
counting eosinophils, which play a central role 
in allergic inflammation. In a meta-analysis of 
the use of induced sputum analysis in adults, the 
technique was shown to be useful in determining 
the use of drugs for asthma prevention, reducing 
the frequency of severe events in patients with 
symptoms that are more severe, that is, in those 
suspected of having bronchial inflammation that 
is more severe.(15) 
Oxidative stress is intimately associated with 
the inflammatory process and results from an 
imbalance between oxidants and antioxidants, 
particularly when the cell membrane is affected, 
in a phenomenon designated lipid peroxidation. 
Malondialdehyde is a by-product of this reaction 
and can be detected, for instance, in workers 
with occupational respiratory disease by using 
another method for quantifying the products 
of respiration: analysis of exhaled breath 
condensate.(16) Patients with asbestosis also 
present with increased inflammatory markers, 
such as hydrogen peroxide and elevated total 
protein levels.(17) In this technique, the air that 
is exhaled undergoes freezing or cooling. The 
resulting material (condensate) is believed 
to reflect the characteristics of the epithelial 
lining fluid and the bronchial mucosa. Exhaled 
breath condensate has been analyzed in studies 
of interstitial lung disease, cancer, and acute 
respiratory failure; however, special attention 
should be paid to the degree and velocity of 
cooling of the fluid in exhaled breath, since 
the measurements can vary.(18) In cases of COPD 
and asthma, the analysis of exhaled breath 
condensate allows the evaluation of substances 
such as prostanoids and eicosanoids. In asthma 
patients, there are no changes in the levels of 
prostaglandins F2α and E2,
(19) whereas these levels 
are elevated in COPD patients.(20) It is possible that 
the opposite is true for leukotriene E4, elevated 
levels of which have been reported in asthma 
patients but not in COPD patients.(19) Regarding 
8-isoprostane, which is another oxidative stress 
marker, studies involving children have produced 
contradictory results.(21) Although nitrotyrosine 
and adenosine have also been studied, neither 
has been shown to be a gold standard marker.(22) 
It is possible that a “combination of markers”(6) 
is required in order to differentiate asthma 
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In a study conducted in 2007, a new device 
was used—the same as that used in the present 
study—and was shown to be extremely easy 
to use.(9) The device dispenses with the use of 
mouthpieces, special sensors, and calculations 
to determine study points on the EBT increase 
curve.(30) In order to differentiate patients with 
asthma from those without, measurement of the 
EBT plateau, as performed by this device, seems 
to be more reliable. Another advantage is that 
the device can maintain the temperature in an 
isolated chamber, with less interference from the 
external temperature. Rigorous control of the 
external temperature was a concern in studies 
using other methods.(7,8) 
Due to the small number of patients 
investigated in the present study, we still cannot 
affirm that the measurement of EBT is a valid 
biological marker for the evaluation of asthma 
control. However, this measurement might 
constitute a new line of research that, after 
further studies, might produce a method to be 
used in routine clinical practice, especially if the 
device employed is portable and easy to use. 
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